Hypothesis

The histone lysine demethylase KDM6B functions as a NAD+-sensitive epigenetic gatekeeper that integrates mitochondrial status with nuclear chromatin states. When NAD+ declines, reduced SIRT1 activity fails to restrain KDM6B, leading to increased H3K27me3 demethylation at promoters of mitochondrial quality‑control genes (e.g., RAB32, RHOT2). This epigenetic shift suppresses mitophagy and biogenesis, elevating ROS, which in turn oxidizes NAD+‑consuming enzymes and further lowers NAD+. The resulting bistable loop locks cells into a self‑reinforcing state of epigenetic drift and mitochondrial failure, thereby driving the coordinated emergence of aging hallmarks.

Mechanistic Rationale

• NAD+–SIRT1–KDM6B axis: SIRT1 deacetylates KDM6B, reducing its enzymatic activity [4]. Falling NAD+ diminishes SIRT1, lifting this brake and allowing KDM6B to erase repressive H3K27me3 marks.
• Target specificity: KDM6B preferentially acts on enhancers of nuclear‑encoded mitochondrial genes. Loss of H3K27me3 at these sites correlates with transcriptional downregulation observed in aged tissues [7].
• ROS feedback: Mitochondrial ROS oxidize intracellular NAD+ to NADH and activate PARP, accelerating NAD+ consumption [5]. Elevated ROS also impair TET enzymes, skewing DNA methylation toward an aged pattern.
• Bistability: Mathematical modeling predicts two stable states—youthful (high NAD+, low KDM6B activity, robust mitochondria) and aged (low NAD+, high KDM6B activity, fragmented mitochondria)—with a sharp transition triggered by modest NAD+ depletion.

Testable Predictions

1. Genetic perturbation: Overexpressing a NAD+-resistant, catalytically dead KDM6B mutant in mouse muscle will prevent age‑related loss of H3K27me3 at mitochondrial genes, preserve NAD+ levels, and delay onset of sarcopenia and insulin resistance.
2. Pharmacological rescue: Treating aged mice with a SIRT1 activator (e.g., SRT2104) together with a NAD+ precursor (NR) should synergistically reduce KDM6B activity, restore H3K27me3, improve mitochondrial respiration, and lower circulating inflammatory cytokines more effectively than either intervention alone.
3. Biomarker correlation: In human longitudinal blood samples, the ratio of KDM6B‑target H3K27me3 loss to plasma NAD+ will predict biological age (as measured by epigenetic clocks) better than either metric alone, and will change prior to clinical onset of age‑related frailty.
4. Directionality test: Inducing acute mitochondrial ROS burst in young cultured fibroblasts via antimycin A will rapidly decrease NAD+, increase KDM6B binding at mitochondrial gene promoters (ChIP‑seq), and precede detectable H3K27me3 loss, establishing ROS as an upstream trigger.

Falsifiability

If any of the following observations hold, the hypothesis is weakened:

• KDM6B manipulation does not alter H3K27me3 at mitochondrial gene promoters despite changes in NAD+ or SIRT1 activity.
• Elevating NAD+ fails to modulate KDM6B‑dependent gene expression in aged tissues.
• The predicted bistable switch is absent; instead, epigenetic and mitochondrial changes vary independently across single cells.
• Human biomarker studies show no temporal precedence of KDM6B‑related epigenetic shifts over NAD+ decline or functional aging metrics.

By positioning KDM6B as a NAD+-sensitive epigenetic integrator of mitochondrial signals, this hypothesis offers a concrete, experimentally tractable node that could explain why interventions targeting epigenetics or mitochondria often produce broad, systemic rejuvenation.